



#13

Attorney Docket No.: 6116.200-US.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Keith Anderson et al.

Serial No.: 09/757,788

Group Art Unit: 1614

Filed: January 10, 2001

Examiner: To be assigned

Confirmation No. 8259

For: Transepithelial Delivery Of GLP-1 Derivatives

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents
Washington, DC 20231

Sir:

It is respectfully requested that the time for response to the Notice to Comply with Sequence Rules dated October 11, 2002 be extended for a period of 1 months from November 11, 2002, to December 11, 2002. Applicant(s) hereby petition(s) for such extension of time.

In the event that an additional extension of time is required, Applicant(s) hereby petition(s) for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

12/16/2002 MBLANCO 00000004 141447 09757788

01 FC:1251 110.00 CH

Please charge the required fee, estimated to be \$110, with this application and to credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: December 11, 2002

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800



23650

PATENT TRADEMARK OFFICE